Fundrise Fund Falls Mania: VCX Slumps 45% as IPO Mania Fades
The Fundrise VCX fund, once a magnet for IPO-obsessed investors, dropped 45% from its peak as market enthusiasm for p...
When Should You Consider A Financial Advisor
Knowing when to consider a financial advisor can make a difference in achieving your financial goals. Be proactive in your planning.
26,299 articlesSportradar (SRAD) 2026 Earnings Outlook for Investors
Sportradar is at a pivotal moment as 2026 earnings unfold. This guide breaks down the numbers, the drivers behind gro...
Staggering Number Jensen Huang Reframes AI Investing
Nvidia CEO Jensen Huang describes a 1,000% surge in AI compute for agentic AI, triggering a broad rethink of data cen...
Intel Doubled AMD’s 2026 Gains, Should You Rebalance Now?
Intel has surged ahead in 2026, outpacing AMD by more than double in year-to-date gains. The rally prompts investors ...
This Alphabet-Heavy Fund Front-Row to AI Boom Surges
A concentrated AI-focused fund with a heavy tilt to Alphabet has surged as demand for AI infrastructure and software ...
ScrollTech Tops Deloitte’s Fastest-Growing Software Firm
ScrollTech earns Deloitte’s nod as the fastest-growing software firm in North America and launches a pre-IPO round ti...
Cony’s 100% Yield Hides Decline Beyond Distributions
CONY’s eye-popping payouts mask a much steeper NAV decline. A 37% drop since inception signals a structural risk behi...
Petrobras’ Yield ECOW Masks a Risky Bet on Brazil Taxes
As Brazil debates new export taxes, ECOW’s big distributions spotlight a yield that may hide political and commodity ...
This Semiconductor Only Need to Ride the AI Wave: ETFs in Focus
A narrow semiconductor ETF has surged as AI demand drives capex in data centers. This semiconductor only need to prov...
SpaceX Looks Reshuffle Deck: A $60B Cursor Deal Transforms Investing
SpaceX is expanding beyond rockets with a bold $60B Cursor deal. This strategic shift could redefine how investors va...
Stock Market Today, Feb: ImmunityBio Up on Anktiva EU OK
ImmunityBio sails higher after the EU green lights ANKTIVA for bladder cancer, igniting waves across biotech stocks. ...
PTIR Investors Lost While Palantir Fell 14% Over Year
PTIR's double-leveraged bet on Palantir underperformed the stock by nearly half over the past year, underscoring the ...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status